Nothing Special   »   [go: up one dir, main page]

EP2534187A1 - Pansement à libération de principe actif - Google Patents

Pansement à libération de principe actif

Info

Publication number
EP2534187A1
EP2534187A1 EP11702068A EP11702068A EP2534187A1 EP 2534187 A1 EP2534187 A1 EP 2534187A1 EP 11702068 A EP11702068 A EP 11702068A EP 11702068 A EP11702068 A EP 11702068A EP 2534187 A1 EP2534187 A1 EP 2534187A1
Authority
EP
European Patent Office
Prior art keywords
wound dressing
mol
foam
dressing according
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11702068A
Other languages
German (de)
English (en)
Inventor
Jan SCHÖNBERGER
Michael Mager
Heike Heckroth
Doris Klee
Mona Wambach
Christoph Suschek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Priority to EP11702068A priority Critical patent/EP2534187A1/fr
Publication of EP2534187A1 publication Critical patent/EP2534187A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/10—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
    • C08G18/12—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step using two or more compounds having active hydrogen in the first polymerisation step
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/00051—Accessories for dressings
    • A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/01—Non-adhesive bandages or dressings
    • A61F13/01008—Non-adhesive bandages or dressings characterised by the material
    • A61F13/01017—Non-adhesive bandages or dressings characterised by the material synthetic, e.g. polymer based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/425—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/2805—Compounds having only one group containing active hydrogen
    • C08G18/2815—Monohydroxy compounds
    • C08G18/283—Compounds containing ether groups, e.g. oxyalkylated monohydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/4009—Two or more macromolecular compounds not provided for in one single group of groups C08G18/42 - C08G18/64
    • C08G18/4018—Mixtures of compounds of group C08G18/42 with compounds of group C08G18/48
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/42—Polycondensates having carboxylic or carbonic ester groups in the main chain
    • C08G18/4244—Polycondensates having carboxylic or carbonic ester groups in the main chain containing oxygen in the form of ether groups
    • C08G18/4247—Polycondensates having carboxylic or carbonic ester groups in the main chain containing oxygen in the form of ether groups derived from polyols containing at least one ether group and polycarboxylic acids
    • C08G18/425—Polycondensates having carboxylic or carbonic ester groups in the main chain containing oxygen in the form of ether groups derived from polyols containing at least one ether group and polycarboxylic acids the polyols containing one or two ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/42—Polycondensates having carboxylic or carbonic ester groups in the main chain
    • C08G18/44—Polycarbonates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/48—Polyethers
    • C08G18/4804—Two or more polyethers of different physical or chemical nature
    • C08G18/4808—Mixtures of two or more polyetherdiols
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/48—Polyethers
    • C08G18/4854—Polyethers containing oxyalkylene groups having four carbon atoms in the alkylene group
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
    • C08G18/72—Polyisocyanates or polyisothiocyanates
    • C08G18/721—Two or more polyisocyanates not provided for in one single group C08G18/73 - C08G18/80
    • C08G18/722—Combination of two or more aliphatic and/or cycloaliphatic polyisocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00727—Plasters means for wound humidity control
    • A61F2013/00731—Plasters means for wound humidity control with absorbing pads
    • A61F2013/0074—Plasters means for wound humidity control with absorbing pads containing foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00902—Plasters containing means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/114—Nitric oxide, i.e. NO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/21—Acids
    • A61L2300/214—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets

Definitions

  • the invention relates to a drug-releasing wound dressing.
  • wound dressings from foams for the treatment of weeping wounds is state of the art. Due to their high absorbency and good mechanical properties see especially polyurethane foams are used by reacting mixtures of diisocyanates and polyols or NCO-functional polyurethane prepolymers with water in the presence of certain catalysts and (foam) additives can be produced. Examples of such wound dressings are described, for example, in US Pat. Nos. 3,978,266, 3,975,567 and EP-A 0 059 048. Wound dressings containing an active ingredient are also known in the prior art. These active substances are, for example, compounds which promote wound healing. Also known is the use of antibacterial or analgesic agents.
  • An active substance-containing wound dressing is described, for example, in WO 2007 068492 A1.
  • the known wound dressings are impregnated with the respective active ingredients in most cases or impregnated therewith. This has the consequence that when they are used initially a large amount of the drug is released, but the discharge rate then drops quickly. It would be desirable, however, for the wound dressing to deliver the contained active ingredient continuously in an almost constant amount over the entire duration of use, as this would assist the healing process in an optimum manner. However, this is not possible with the known wound dressings, especially when using readily water-soluble active ingredients.
  • EP 0 436 729 A1 again discloses a bandage containing active ingredient-containing microcapsules.
  • the microcapsules here consist of water-resistant, heat-cured resins. Release of the active substance can therefore only take place if the microcapsules are destroyed mechanically, for example by friction. Then the release takes place abruptly. A continuous release of the active ingredient is therefore not given.
  • the object of the invention was to provide a wound dressing which allows a continuous, quantitatively almost constant delivery of an optionally present, in particular water-soluble, active ingredient over the entire intended period of use.
  • a wound dressing comprising a liquid-absorbing substrate with active substance depots contained therein, wherein the active ingredient depots comprise particles of at least one active ingredient that are encapsulated in a silicone casing.
  • the wound dressings according to the invention continuously release an almost uniformly large amount of the active substance contained in the active substance depot so that an optimal supply of the supplied wound to the active ingredient takes place.
  • the substrate is a foam. It is advantageous that the substrate on the one hand has a high absorption capacity for discharged from the wound fluids and on the other hand can adapt particularly well elastic to the wound.
  • the foam may in particular have a density of 0.5, preferably of 0.4, more preferably of> 0.01 to ⁇ 0.3 and particularly preferably of> 0.05 to ⁇ 0.3 g / cm 3 .
  • Wound dressings which have such a foam as a substrate are characterized by a particularly high absorption capacity and particularly advantageous mechanical properties.
  • the foam may be a polymer based foam, preferably a reactive foam or a blown foam.
  • the foam is based on polyurethanes.
  • Suitable polyurethanes are obtainable by reacting A) isocyanate-functional prepolymers having a weight fraction of low molecular weight, aliphatic diisocyanates having a molar mass of 140 to 278 g / mol of less than 1.0 wt .-%, based on the prepolymer, by reacting
  • G optionally monohydric or polyhydric alcohols and
  • Hl low molecular weight, aliphatic diisocyanates having a molecular weight of 140 to 278 g / mol and / or polyisocyanates obtainable therefrom having an isocyanate functionality of 2 to 6 with
  • H2 monofunctional polyalkylene oxides having an OH number of 10 to 250 and an ethylene oxide content of 50 to 100 mol%, based on the total amount of oxyalkylene groups contained. available.
  • these polyurethanes it is possible in particular to produce reactive foams which are particularly suitable for use as a substrate in the wound dressing according to the invention because of their high absorption capacity for liquids delivered by the wound.
  • the prepolymers used in A) preferably have a residual monomer content of less than 0.5% by weight, based on the prepolymer. This content can be achieved by appropriately selected amounts of Al) and A2). However, the use of isocyanate is preferred. Anats AI) in excess and subsequent, preferably distillative, separation of unreacted monomers.
  • the preparation of the isocyanate-functional prepolymers of component A) is typically carried out by reacting one equivalent of PolyoUcomponente A2), based on the hydroxyl function, with one to 20 mol, preferably one to 10 mol, particularly preferably 5 to 10 mol, of the low molecular weight aliphatic diisocyanate AI).
  • the reaction can be carried out in the presence of urethanization catalysts such as tin compounds, zinc compounds, amines, guanidines or amidines, or in the presence of allophanatization catalysts such as zinc compounds.
  • urethanization catalysts such as tin compounds, zinc compounds, amines, guanidines or amidines
  • allophanatization catalysts such as zinc compounds.
  • the reaction is typically carried out at 25 to 140 ° C, preferably at 60 to 100 ° C.
  • Acidic or alkylating stabilizers such as benzoyl chloride, isophthaloyl chloride, methyl tosylate, chloropropionic acid, HCl or antioxidants such as di-tertiary-butyl-cresol or tocopherol may be added before, during and after the reaction or by distillation of the excess diisocyanate.
  • the NCO content of the isocyanate-functional prepolymers A) is preferably from 1.5 to 4.5% by weight, more preferably from 1.5 to 3.5% by weight and very particularly preferably from 1.5 to 3.0% by weight. %.
  • low molecular weight aliphatic diisocyanates of component AI are hexamethylene diisocyanate (HDI), isophorone diisocyanate (IPDI), butylene diisocyanate (BDI), bis-isocyanatocyclohexylmethane (HMDI), 2,2,4-trimethylhexamethylene diisocyanate, bisisocyanato-methylcyclohexane, bisisocyanatomethyltricyclodecane, xylene diisocyanate, tetramethylxylylene - Diisocyanate, norbornane diisocyanate, cyclohexane diisocyanate or diisocyanatododecane, wherein
  • Hexamethylene diisocyanate (HDI), isophorone diisocyanate (IPDI), butylene diisocyanate (BDI) and bis (isocyanatocyclohexyl) methane (HMDI) are preferred. Particularly preferred are hexamethylene diisocyanate, isophorone diisocyanate, butylene diisocyanate, most preferably hexamethylene diisocyanate and isophorone diisocyanate.
  • Polyalkylene oxides of component A2) are preferably copolymers of ethylene oxide and propylene oxide having an ethylene oxide content, based on the total amount of the oxyalkylene groups contained, of from 50 to 100 mol%, preferably from 60 to 85 mol%, started on polyols or amines.
  • Suitable initiators of this type are glycerol, trimethylolpropane (TMP), sorbitol, pentaerythritol, triethanolamine, ammonia or ethylenediamine.
  • the polyalkylene oxides of component A2) typically have number-average molecular weights of from 1000 to 15000 g / mol, preferably from 3000 to 8500 g / mol.
  • the polyalkylene oxides of component A2) have OH functionalities of from 2 to 6, preferably from 3 to 6, more preferably from 3 to 4.
  • Compounds of component B) which may be used are heterocyclic, 4-ring or 6-membered oligomers of low molecular weight, aliphatic diisocyanates having a molecular weight of 140 to 278 g / mol such as isocyanurates, Iminooxadiazindione or uretdiones of the aforementioned low molecular weight, aliphatic diisocyanates. Preference is given to heterocyclic 4-ring oligomers such as uretdiones.
  • the increased content of isocyanate groups through the use of component B) ensures better foaming by more CO 2 formed from the isocyanate-water reaction.
  • the water to be used as component C) can be used as such, as the water of crystallization of a salt, as a solution in a dipolar aprotic solvent or else as an emulsion.
  • the water is preferably used as such or in a dipolar aprotic solvent. Most preferably, the water is used as such.
  • catalysts can be used in component D). These are typically the compounds known to those skilled in polyurethane technology. Preference is given here to compounds of the group consisting of catalytically active metal salts, amines, amidines and guanidines. Exemplary are tin dibutyl dilaurate (DBTL), tin octoate (SO), tin acetate, zinc octoate (ZO), 1,8-
  • Diazabicyclo [5.4.0] undecene-7 (DBU), 1, 5-diazabicyclo [4.3.0] nonene-5 (DBN), 1, 4-diazabicyclo [3.3.0] octene-4 (DBO) , N-ethylmorpholine (NEM), triethylenediamine (DABCO), pentamethylguanidine (PMG), tetrametylguanidine (TMG), cyclotetramethylguanidm (TMGC), n-decyl-tetramethylguanidine (TMGD), n-dodecyltetramethylguanidine (TMGDO), dimethylaminoethyltetramethylguanidine (TMGN), 1 , 1,4,4,5,5-hexamethylisobiguanidine (HMIB), phenyltetramethylguanidine (TMGP) and hexamethylenoctamethylbiguanidine (HOBG).
  • DBU dimethylguanidine
  • amines particularly preferred is the use of amines, amidines, guanidines or mixtures thereof as catalysts of component D).
  • DBU 1,8-diazabicyclo [5.4.0] undecene-7
  • component E) are ammonium and alkali metal salts of C & to C22 monocarboxylates or their free carboxylic acids or Cn to C44 dicarboxylates or their free dicarboxylic acids, preferably potassium or sodium salts of C & to C22 monocarboxylates or Cn - C44-dicarboxylates, and more preferably sodium salts of C & to C22 mono-carboxylates used.
  • suitable compounds of component E) are the ammonium, Na, Li or K salts of ethylhexanoic, octanoic, decanoic, dodecanoic, palmitic, stearic, octadecenoic, octadecadienoic, octadecatrienoic, isostearic, erucic and abietic acids and their hydrogenation products.
  • C 1 - to C 44 -dicarboxylic acids or the ammonium and alkali salts derived therefrom are dodecanedioic acid, dodecenyl-, tetradecenyl-, hexadecenyl- and octadecenyl-succinic acid, C 36- and C 44 -dimer fatty acids and their hydrogenation products, and the corresponding ammonium, Na, Li or K salts of these dicarboxylic acids.
  • compounds of component F can be used, wherein such additives may in principle be any anionic, cationic, amphoteric and nonionic surfactants known per se and mixtures thereof.
  • Alkyl polyglycosides, EO / PO block copolymers, alkyl or aryl alkoxylates, siloxane alkoxylates, esters of sulfosuccinic acid and / or alkali metal or alkaline earth metal alkanoates are preferably used. Particular preference is given to using EO / PO block copolymers. Preferably, only the EO / PO block copolymers are used as component F).
  • compounds of component G) can be used to improve the foam properties of the resulting polyurethane foam.
  • monohydric and polyhydric alcohols known to the person skilled in the art and mixtures thereof.
  • mono- or polyhydric alcohols or polyols such as ethanol, Propanol, butanol, decanol, tridecanol, hexadecanol, ethylene glycol, neopentyl glycol, butanediol, hexanediol, decanediol, trimethylolpropane, glycerol, pentaerythritol, monofunctional polyether alcohols and polyester alcohols, polyether diols and polyester diols.
  • the ratio of the monofunctional polyalkylene oxides H2) to the low molecular weight, aliphatic diisocyanates Hl is typically adjusted so that for 1 mol OH groups of monofunctional polyalkylene oxides 1, 25 to 15 mol, preferably 2 to 10 mol and more preferably 2 to 6 moles NCO groups of the low molecular weight, aliphatic diisocyanate Hl) come. This is followed by allophanatization or biurization and / or isocyanurate formation or uretdione formation. If the polyalkylene oxides H2) are bound to the aliphatic diisocyanates H1 via urethane groups, allophanatization preferably takes place subsequently. It is further preferred that isocyanurate structural units are formed.
  • hydrophilic polyisocyanates H) is typically carried out by reacting 1 mol of OH groups of the monofunctional polyalkylene oxide component H2) with 1.25 to 15 mol, preferably 2 to 10 mol and more preferably 2 to 6 mol NCO groups of a polyisocyanate Hl). with an isocyanate functionality of 2 to 6 based on aliphatic diisocyanates.
  • Exemplary of such polyisocyanates HI) are biuret structures, isocyanurates or uretdiones based on aliphatic diisocyanates.
  • the polyisocyanates H1) and the polyalkylene oxides H2) are preferably linked to one another via a urethane group or a urea group, the linking via urethane groups in particular being preferred.
  • the reaction can be carried out in the presence of urethanization catalysts such as tin compounds, zinc compounds, amines, guanidines or amidines, or in the presence of allophanatization catalysts such as zinc compounds.
  • urethanization catalysts such as tin compounds, zinc compounds, amines, guanidines or amidines
  • allophanatization catalysts such as zinc compounds.
  • the reaction is typically carried out at 25 to 140 ° C, preferably at 60 to 100 ° C.
  • acidic or alkylating stabilizers such as benzoyl chloride, isophthaloyl chloride, methyl tosylate, chloropropionic acid, HCl or antioxidants such as di-ferric butylcresol or tocopherol.
  • the NCO content (determined according to DIN-EN ISO 11909) of the hydrophilic polyisocyanates H) is preferably 0.3 to 20% by weight, more preferably 2 to 10% by weight and very particularly preferably 3 to 6% by weight. -%.
  • low molecular weight, aliphatic diisocyanates of component HI are hexamethylene diisocyanate (HDI), isophorone diisocyanate (IPDI), butylene diisocyanate (BDI), bis-isocyanatocyclohexylmethane (HMDI), 2,2,4-trimethylhexamethylene diisocyanate, bisisocyanato-methylcyclohexane, bisisocyanatomethyltricyclodecane, xylene diisocyanate , Tetramethylxylylene diisocyanate, norbornane diisocyanate, cyclohexane diisocyanate or diisocyanatododecane, wherein
  • Hexamethylene diisocyanate (HDI), isophorone diisocyanate (IPDI), butylene diisocyanate (BDI) and bis (isocyanatocyclohexyl) methane (HMDI) are preferred. Particularly preferred are hexamethylene diisocyanate (HDI), isophorone diisocyanate (IPDI), butylene diisocyanate (BDI), most preferably hexamethylene diisocyanate (HDI) and isophorone diisocyanate (IPDI).
  • Examples of relatively high molecular weight polyisocyanates H1) are polyisocyanates having an isocyanate functionality of 2 to 6 with isocyanurate, urethane, allophanate, biuret, iminooxadiazinetrione, oxadiazinetrione and / or uretdione groups, based on the aliphatic and / or uretidione groups mentioned in the preceding section. or cycloaliphatic diisocyanates.
  • component HI relatively high molecular weight compounds having biuret, iminoxadiazinedione, isocyanurate and / or uretdione groups based on hexamethylene diisocyanate, isophorone diisocyanate and / or 4,4'-diisocyanatodicyclohexylmethane are preferably used. Further preferred are isocyanurates. Very particular preference is given to structures based on hexamethylene diisocyanate.
  • Suitable starter molecules are in particular saturated monoalcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, sec-butanol, diethylene glycol monobutyl ether and aromatic alcohols such as phenol or monoamines such as diethylamine.
  • Preferred starter molecules are saturated monoalcohols Diethylenglykolmonobutylether or n-butanol are particularly preferably used as starter molecules.
  • monofunctional polyalkylene oxides are meant here compounds which are only one isocyanate-reactive group, i. a group capable of reacting with an NCO group.
  • the monofunctional polyalkylene oxides H2) preferably have an OH group as the isocyanate-reactive group.
  • the monofunctional polyalkylene oxides H2) have an OH number of from 15 to 250, preferably from 28 to 112, and an ethylene oxide content of from 50 to 100 mol%, preferably from 60 to 100 mol%, based on the total amount of the oxyalkylene groups present.
  • the monofunctional polyalkylene oxides H2) typically have number-average molecular weights of from 220 to 3700 g / mol, preferably from 500 to 2800 g / mol.
  • the preparation of reactive foams from the aforementioned polyurethanes can by mixing the components A), C) and optionally B), D), E), F), G), H) in any order, foaming the mixture and curing, preferably by chemical crosslinking, done.
  • the components A), B) and optionally H) are preferably premixed with one another.
  • the components E) and optionally F) can be added to the reaction mixture in the form of their aqueous solutions.
  • the foaming can in principle be carried out by the carbon dioxide formed in the reaction of the isocyanate groups with water, but the use of further blowing agents is likewise possible.
  • blowing agents from the class of hydrocarbons such as C3-C6 alkanes, for example, butane, pentane, zso-pentane, cyc7o-pentane, hexanes or the like.
  • halogenated hydrocarbons such as dichloromethane, dichloromonofluoromethane, chlorodifluoroethanes, 1,1-dichloro-2,2,2-trifluoroethane, 2,2-dichloro-2-fluoroethane, in particular chlorine-free fluorohydrocarbons, such as difluoromethane, trifluoromethane, difluoroethane, 1, 1, 1, 2-tetrafluoroethane, tetrafluoroethane (R 134 or R 134a), 1,1,1,3,3-pentafluoropropane (R 245 fa), 1,1,1,3,3,3-hexafluoropropane (R 256), 1,1,1,3,3-pentafluorobutane (R 365 mfc), heptafluoropropane or sulfur hexafluoride can be used. It is also possible to use mixtures of these blowing agents. Subsequent cu
  • polyurethanes can be used which are available by
  • polymeric polyols having number average molecular weights of 400 to 8000 g / mol and OH functionalities of 1.5 to 6 and
  • step J2 isocyanate-reactive, preferably amino-functional, anionic or potentially anionic hydrophilicizing agents are reacted with chain extension and the prepolymers before, during or after step J) are dispersed in water, optionally containing potentially ionic groups by partial or complete reaction with a neutralizing agent in the ionic form be transferred.
  • polyurethanes can be used in the form of aqueous dispersions, in particular for the production of blow foams, which are also distinguished by a high absorption capacity for fluids released from the wound when used as a substrate for the wound dressing according to the invention.
  • Suitable polyisocyanates of component II) are the aromatic, araliphatic, aliphatic or cycloaliphatic polyisocyanates of an NCO functionality of> 2 which are known per se to the person skilled in the art.
  • suitable polyisocyanates are 1,4-butylene diisocyanate, 1,6-hexamethylene diisocyanate (HDI), isophorone diisocyanate (IPDI), 2,2,4 and / or 2,4,4-trimethylhexamethylene diisocyanate, the isomeric bis (4 , 4'-isocyanatocyclohexyl) methanes or mixtures thereof of any isomer content, 1,4-cyclohexylene diisocyanate, 1,4-phenylenediisocyanate, 2,4- and / or 2,6-toluene diisocyanate, 1,5-naphthylene diisocyanate, 2,2 ' -and or
  • 2,4'- and / or 4,4'-diphenylmethane diisocyanate 1,3- and / or 1,4-bis (2-isocyanato-prop-2-yl) -benzene (TMXDI), 1, 3-bis (isocyanatomethyl) benzene (XDI), alkyl 2,6-diisocyanatohexanoate (lysine diisocyanates) with C l -C 8 -alkyl groups, and also 4-isocyanatomethyl-l, 8-octane diisocyanate (nonane triisocyanate) and triphenylmethane-4,4 ', 4 "- triisocyanate.
  • modified diisocyanates or triisocyanates having uretdione, isocyanurate, urethane, allophanate, biuret, iminooxadiazinedione and / or oxadiazinetrione structures.
  • polyisocyanates or polyisocyanate mixtures of the abovementioned type having exclusively aliphatically and / or cycloaliphatically bonded isocyanate groups and an average NCO functionality of the mixture of 2 to 4, preferably 2 to 2.6 and particularly preferably 2 to 2.4 ,
  • polymeric polyols having a number average molecular weight Mn of preferably from 400 to 6000 g / mol and more preferably from 600 to 3000 g / mol are used. These preferably have an OH functionality of from 1.8 to 3, particularly preferably from 1.9 to 2.1.
  • Such polymeric polyols are the polyester polyols known per se in polyurethane coating technology, polyacrylate polyols, polyurethane polyols, polycarbonate polyols, polyether polyols, polyester polyacrylate oils, polyurethane polyacrylate polyols, polyurethane polyester polyols, polyurethane polyether polyols, polyurethane polycarbonate polyols and polyester polycarbonate polyols. These can be used in A2) individually or in any mixtures with each other.
  • Polyester polyols are, for example, the known polycondensates of di- and optionally tri- and tetraols and di- and optionally tri- and tetracarboxylic acids or hydroxycarboxylic acids or lactones.
  • free polycarboxylic acids it is also possible to use the corresponding polycarboxylic acid anhydrides or corresponding polycarboxylic acid esters of lower alcohols for the preparation of the polyesters.
  • diols examples include ethylene glycol, butylene glycol, diethylene glycol, triethylene glycol, polyalkylene glycols such as polyethylene glycol, furthermore 1,2-propanediol, 1,3-propanediol, butanediol (1,3), butanediol (1,4), hexanediol (I, 6) and isomers, neopentyl glycol or hydroxypivalic acid neopentyl glycol esters, with hexanediol (1,6) and isomers, neopentyl glycol and hydroxypivalic acid neopentyl glycol ester being preferred.
  • polyalkylene glycols such as polyethylene glycol, furthermore 1,2-propanediol, 1,3-propanediol, butanediol (1,3), butanediol (1,4), hexanediol (I,
  • polyols such as trimethylolpropane, glycerol, erythritol, pentaerythritol, trimethylolbenzene or trishydroxyethyl isocyanurate.
  • Suitable dicarboxylic acids are phthalic acid, isophthalic acid, terephthalic acid, tetrahydrophthalic acid, hexahydrophthalic acid, cyclohexanedicarboxylic acid, adipic acid, azelaic acid, sebacic acid, glutaric acid, tetrachlorophthalic acid, maleic acid, fumaric acid, itaconic acid, malonic acid, suberic acid, 2-methylsuccinic acid, 3,3-diethylglutaric acid and / or 2,2-dimethylsuccinic acid.
  • the acid source used may also be the corresponding anhydrides.
  • the average functionality of the polyol to be esterified is greater than 2, it is additionally possible to use monocarboxylic acids, such as benzoic acid and hexanecarboxylic acid.
  • Preferred acids are aliphatic or aromatic acids of the abovementioned type. Particular preference is given to adipic acid, isophthalic acid and, if appropriate, trimellitic acid.
  • Hydroxycarboxylic acids which can be used as reactants in the preparation of a hydroxyl-terminated polyester polyol include hydroxycaproic acid, hydroxybutyric acid, hydroxydecanoic acid, hydroxystearic acid and the like.
  • Suitable lactones are caprolactone, butyrolactone and homologs. Preference is given to caprolactone.
  • hydroxyl-containing polycarbonates preferably polycarbonatediols, having number-average molecular weights Mn of from 400 to 8000 g / mol, preferably from 600 to 3000 g / mol.
  • carbonic acid derivatives such as diphenyl carbonate, dimethyl carbonate or phosgene
  • polyols preferably diols, available.
  • diols examples include ethylene glycol, 1,2- and 1,3-propanediol, 1,3- and 1,4-butanediol, 1,6-hexanediol, 1,8-octanediol, neopentyl glycol, 1,4-bis-hydroxymethylcyclohexane, 2- Methyl-l, 3-propanediol, 2,2,4-Trimethylpentandiol-l, 3, dipropylene glycol, polypropylene glycols, dibutylene glycol, polybutylene glycols, bisphenol A and lactone-modified diols of the type mentioned above.
  • the polycarbonate diol preferably contains from 40 to 100% by weight of hexanediol, preferably 1,6-hexanediol and / or hexanediol derivatives, based on the diols which are the base.
  • hexanediol derivatives are based on hexanediol and have ester or ether groups in addition to terminal OH groups.
  • Such derivatives are obtainable by reaction of hexanediol with excess caprolactone or by etherification of hexanediol with itself to give di- or trihexylene glycol.
  • polyether-polycarbonate diols instead of or in addition to pure polycarbonate diols, it is also possible to use polyether-polycarbonate diols in 12).
  • the hydroxyl-containing polycarbonates are preferably built linear.
  • polyether polyols can be used. Suitable examples are the polytetramethylene glycol polyethers known per se in polyurethane chemistry, such as are obtainable by polymerization of tetrahydrofuran by means of cationic ring opening. Also suitable polyether polyols are the per se known addition products of styrene oxide, ethylene oxide, propylene oxide, butylene oxides and / or epichlorohydrin to di- or polyfunctional starter molecules.
  • starter molecules it is possible to use all compounds known from the prior art, for example water, butyl diglycol, glycerol, diethylene glycol, trimethylolpropane, propylene glycol, sorbitol, ethylenediamine, triethanolamine, 1,4-butanediol.
  • Preferred starter molecules are water, ethylene glycol, propylene glycol, 1,4-butanediol, diethylene glycol and butyl diglycol.
  • the polyurethanes contain, as component 12), a mixture of polycarbonate polyols and polytetramethylene glycol polyols, the proportion of polycarbonate polyols in the mixture being from 20 to 80% by weight and the proportion of polytetra methylene glycol polyols from 80 to 20% by weight in this mixture. is. Preference is given to a proportion of 30 to 75 wt .-% of polytetramethylene glycol polyols and a content of 25 to 70 wt .-% of polycarbonate polyols.
  • a proportion of 35 to 70% by weight of polytetra methylene glycol polyols and a proportion of 30 to 65% by weight of polycarbonate polyols in each case with the proviso that the sum of the percentages by weight of the polycarbonate and polytetramethylene glycol polyols is 100%. and the proportion of the sum of the polycarbonate and Polytetramethylenglykolpolyetherpolyole to the component 12) is at least 50 wt .-%, preferably 60 wt .-% and particularly preferably at least 70 wt .-%.
  • polyols of said molecular weight range having up to 20 carbon atoms such as ethylene glycol, diethylene glycol, triethylene glycol, 1, 2-propanediol, 1, 3-propanediol, 1, 4-butanediol, 1, 3-butylene glycol, cyclohexanediol, 1, 4 Cyclohexanedimethanol, 1,6-hexanediol, neopentyl glycol, hydroquinone dihydroxyethyl ether, bisphenol A (2,2-bis (4-hydroxyphenyl) propane), hydrogenated bisphenol A, (2,2-bis (4-hydroxycyclohexyl) propane), trimethylolpropane , Glycerin, pentaerythritol and any mixtures thereof.
  • ethylene glycol diethylene glycol, triethylene glycol, 1, 2-propanediol, 1, 3-propanediol, 1, 4-butanediol, 1, 3-butylene glycol,
  • ester diols of the stated molecular weight range, such as ⁇ -hydroxybutyl- ⁇ -hydroxycaproic acid ester, co-hydroxyhexyl- ⁇ -hydroxybutyric acid ester, adipic acid- ( ⁇ -hydroxyethyl) ester or terephthalic acid bis ( ⁇ -hydroxyethyl) ester.
  • monofunctional, hydroxyl-containing compounds can also be used in 13).
  • monofunctional compounds are ethanol, n-butanol, ethylene glycol monobutyl ether, diethylene glycol monobutyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, dipropylene glycol monomethyl ether, tripropylene glycol monomethyl ether, dipropylene glycol monopropyl ether, propylene glycol monobutyl ether, dipropylene glycol monobutyl ether, tripropylene glycol monobutyl ether, 2-ethylhexanol, 1-octanol , 1-dodecanol, 1-hexadecanol.
  • Preferred compounds of component 13) are 1,6-hexanediol. 1, 4-butanediol, neopentyl glycol and trimethylolpropane.
  • anionically or potentially anionically hydrophilizing compounds of component 14) are meant all compounds which have at least one isocyanate-reactive group such as a hydroxyl group and at least one functionality such as -COO-M + , -S0 3 M + , -PO (O-M + ) 2 with M +, for example, the same metal cation, H + , NH 4 + , NHR 3 + , where R may each be a C 1 -C 12 -alkyl radical, C 5 -C 6 -cycloalkyl radical and / or a C 2 -C 4 -hydroxyalkyl radical which may be present at Interaction with aqueous media enters a pH-dependent dissociation equilibrium and can be charged in this way negative or neutral.
  • Suitable anionic or potentially anionic hydrophilizing compounds are mono- and dihydroxycarboxylic acids, mono- and dihydroxysulfonic acids, as well as mono- and dihydroxyphosphonic acids and their salts.
  • Examples of such anionic or potentially anionic hydrophilicizing agents are dimethylolpropionic acid, dimethylolbutyric acid, hydroxypivalic acid, malic acid, citric acid, glycolic acid, lactic acid and the propoxylated adduct of 2-butenediol and NaHSO 3 , as described in DE-A 2 446 440, page 5 - 9, formula I-III is described.
  • Preferred anionic or potentially anionic hydrophilicizing agents of component 14) are those of the abovementioned type which have carboxylate or carboxylic acid groups and / or sulfonate groups.
  • Particularly preferred anionic or potentially anionic hydrophilicizing agents of component 14) are those which contain carboxylate or carboxylic acid groups as ionic or potentially ionic groups, such as dimethylolpropionic acid, dimethylolbutyric acid and hydroxypivalic acid or salts thereof.
  • Suitable nonionic hydrophilizing compounds of component 14) are e.g. Polyoxyalkylene ethers which contain at least one hydroxyl or amino group, preferably at least one hydroxyl group. Examples are the monohydroxy-functional, on average 5 to 70, preferably 7 to 55 ethylene oxide units per molecule having polyalkylene oxidpolyether alcohols, as they are accessible in a conventional manner by alkoxylation of suitable starter molecules (eg in Ullmann's Encyclopedia of Industrial Chemistry, 4th Edition, Volume 19, Verlag Chemie, Weinheim pp. 31-38).
  • polyethylene oxide ethers or mixed polyalkylene oxide ethers, but they then contain at least 30 mol%, preferably at least 40 mol%, based on all contained alkylene oxide units of ethylene oxide units.
  • Particularly preferred nonionic compounds are monofunctional mixed polyalkylene oxide polyethers which have 40 to 100 mol% of ethylene oxide and 0 to 60 mol% of propylene oxide units.
  • Suitable starter molecules for such nonionic hydrophilicizing agents are saturated monoalcohols, such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, sec-
  • Butanol the isomers pentanols, hexanols, octanols and nonanols, n-decanol, n-dodecanol, n-tetradecanol, n-hexadecanol, n-octadecanol, cyclohexanol, the isomeric methylcyclohexanols or hydroxymethylcyclohexane, 3-ethyl-3-hydroxymethyloxetane or Tetrahydrofurfuryl alcohol, diethylene glycol monoalkyl ethers, such as diethylene glycol monobutyl ether, unsaturated alcohols such as allyl alcohol, 1,1-dimethylallyl alcohol or oleic alcohol, aromatic alcohols such as phenol, the isomeric cresols or methoxyphenols, aliphatic alcohols such as benzyl alcohol, anisalcohol or cinnamyl alcohol, secondary Mono
  • Alkylene oxides which are suitable for the alkoxylation reaction are, in particular, ethylene oxide and propylene oxide, which can be used in any desired order or even as a mixture in the alkoxylation reaction.
  • component JI can di- or polyamines such as 1, 2-ethylenediamine, 1,2- and 1, 3-diaminopropane, 1,4-diaminobutane, 1, 6-diaminohexane, isophoronediamine, isomer mixture of 2,2,4- and 2,4,4-trimethylhexamethylenediamine, 2-methylpentamethylenediamine, diethylenetriamine, triaminononane, 1,3- and 1,4-xylylenediamine, ⁇ , ⁇ , ⁇ ', ⁇ '-tetramethyl-1,3- and
  • 1,4-diaminodicyclohexylmethane and / or dimethylethylenediamine is also possible, but less preferred, is the use of hydrazine or hydrazides such as adipic dihydrazide.
  • component JI compounds which, in addition to a primary amino group, also have secondary amino groups or, in addition to an amino group (primary or secondary), also OH groups, can be used.
  • primary secondary amines such as diethanolamine, 3-amino-1-methylaminopropane, 3-amino-1-ethylaminopropane, 3-amino-1-cyclohexylaminopropane, 3-amino-1-methylaminobutane, alkanolamines such as N-aminoethylethanolamine, ethanolamine , 3-aminopropanol, neopentanolamine.
  • component J1 Also suitable as component J1) are also monofunctional isocyanate-reactive amine compounds, for example methylamine, ethylamine, propylamine, butylamine, octylamine, laurylamine, stearylamine, isononyloxypropylamine, dimethylamine, diethylamine, dipropylamine, dibutylamine, N-methylaminopropylamine, diethyl (methyl) aminopropylamine, morpholine, piperidine, or suitable substituted derivatives thereof, amide amines from diphenylamines and monocarboxylic acids, monoketime of diprimary amines, primary / tertiary amines such as N, N-dimethylaminopropylamine.
  • monofunctional isocyanate-reactive amine compounds for example methylamine, ethylamine, propylamine, butylamine, octylamine, laurylamine, stearylamine
  • Preferred compounds of component JI) are 1, 2-ethylenediamine, 1, 4-diaminobutane and isophoronediamine.
  • anionically or potentially anionically hydrophilizing compounds of component J2) are meant all compounds which have at least one isocyanate-reactive group, preferably an amino group, and at least one functionality such as -COO-M + , -S0 3 M + , -PO (0-M + ) 2 with M +, for example, metal cation, Pf, NH 4 + , NHR, where R may each be a C 1 -C 12 -alkyl radical, C 5 -C 6 -cycloalkyl radical and / or a C 2 -C 4 -hydroxyalkyl radical which may be present at Interaction with aqueous media enters a pH-dependent dissociation equilibrium and can be charged in this way negative or neutral.
  • Suitable anionic or potentially anionic hydrophilizing compounds are mono- and diaminocarboxylic acids, mono- and diaminosulfonic acids and mono- and diaminophosphonic acids and their salts.
  • anionic or potentially anionic hydrophilicizing agents are N- (2-aminoethyl) - ⁇ -alanine, 2- (2-aminoethylamino) ethanesulfonic acid, ethylenediamine-propyl- or -butylsulfonic acid, 1, 2 or 1, 3 Propylene diamine ⁇ -ethylsulfonic acid, glycine, alanine, taurine, lysine, 3,5-diaminobenzoic acid and the addition product of IPDA and acrylic acid (EP-A 0 916 647, Example 1).
  • anionic or potentially anionic hydrophilizing agents of component J2) are those of the abovementioned type which have carboxylate or carobonic acid groups and / or sulfonate groups such as the salts of N- (2-aminoethyl) - ⁇ -alanine, 2- (2 - Aminoethylamino) ethanesulfonic acid or the addition product of IPDA and acrylic acid (EP-A 0 916 647, Example 1).
  • hydrophilization it is also possible to use mixtures of anionic or potentially anionic hydrophilicizing agents and nonionic hydrophilicizing agents.
  • the active ingredient comprises a component which releases nitrogen monoxide under in vivo conditions, preferably L-arginine or an L-arginine-containing or an L-arginine-releasing component, particularly preferably L-arginine hydrochloride.
  • a component which releases nitrogen monoxide under in vivo conditions preferably L-arginine or an L-arginine-containing or an L-arginine-releasing component, particularly preferably L-arginine hydrochloride.
  • Proline, ornithine and / or other biogenic intermediates such as biogenic polyamines (spermine, spermitine, putrescine or bioactive artificial polyamines) can also be used.
  • Such components are known to assist wound healing, with their continuous quantitatively nearly uniform delivery of wound healing being particularly beneficial.
  • Further active substances which can be used according to the invention comprise at least one substance selected from the group of vitamins or provitamins, carotenoids, analgesics, antiseptics, hemostyptics, antihistamines, antimicrobial metals or their salts, plant wound healing substances or substance mixtures, plant extracts, enzymes, growth factors, enzyme inhibitors and combinations thereof.
  • non-steroidal analgesics in particular salicylic acid, acetylsalicylic acid and derivatives thereof such as Aspirin ®, aniline and its derivatives, acetaminophen eg paracetamol ®, anthranilic, and their derivatives such as mefenamic acid, pyrazole or its derivatives, for example, methimazole, Novalgin ®, antipyrine, antipyrine ® , Isopropylphenazone and very particularly preferably arylacetic acids and their derivatives, Heteroarylessigklakla and their derivatives, arylpropionic acids and their derivatives and Herteroarylpropionklaren and their derivatives such as Indometacin ® , Diclophenac ® , Ibuprofen ® , Naxoprophen ® , Indomethacin ® , Ketoprofen ® , Piroxicam ® suitable.
  • Growth factors include: aFGF (Acidic Fibroplast Growth Factor), EGF (Epidermal Growth Factor), PDGF (Platelet Derived Growth Factor), rhPDGF-BB (becaplermin), PDECGF (Platelet Derived Endothelial Cell Growth Factor), bFGF (Basic Fibroplast growth factor), TGF a; (Transforming Growth Factor alpha), TGF (Transforming Growth Factor beta), KGF (Keratinocyte Growth Factor), IGF1 / IGF2 (Insulin-Like Growth Factor) and TNF (Tumor Necrosis Factor).
  • aFGF Acidic Fibroplast Growth Factor
  • EGF Epidermatitis
  • PDGF PlaterhPDGF-BB (becaplermin)
  • PDECGF Platinum Derived Endothelial Cell Growth Factor
  • bFGF Basic Fibroplast growth factor
  • TGF a Transforming Growth Factor alpha
  • TGF Transforming Growth Fact
  • Vitamins or provitamins in particular are the fat-soluble or water-soluble vitamins vitamin A, group of retinoids, provitamin A, group of carotenoids, in particular ⁇ -carotene, vitamin E, group of tocopherols, in particular ⁇ -tocopherol, ⁇ -tocopherol, ⁇ - Tocopherol, ⁇ -tocopherol and ⁇ -tocotrienol, ⁇ -tocotrienol, ⁇ -tocotrienol and ⁇ -tocotrienol, vitamin K, phylloquinone, in particular phytomenadione or vegetable vitamin K, vitamin C, L-ascorbic acid, vitamin B 1, thiamine, vitamin B2, riboflavin , Vitamin G, vitamin B3, niacin, nicotinic acid and nicotinamide, vitamin B5, pantothenic acid, provitamin B5, panthenol or dexpanthenol, vitamin B6, vitamin B7, vitamin H, biotin, vitamin
  • an antiseptic use must be made of such a composition that acts as a stain, bactericide, bacteriostatic, fungicidal, virucidal, virustatic and / or general microbiocidal agent.
  • those substances are suitable which are selected from the group resorcinol, iodine, iodine povidone, chlorhexidine, benzalkonium chloride, benzoic acid, benzoyl peroxide or Cethylpyridiniumchlorid.
  • antiseptics in particular antimicrobial metals are to be used.
  • silver, copper or zinc and their salts, oxides or complexes may be used in combination or alone as antimicrobial metals.
  • extracts of chamomile, witch hazel extracts are used as herbal, wound healing promoting agents.
  • the silicone encapsulation encapsulating the active substance particles may preferably consist of polydimethylsiloxane, polyvinylsiloxane, polyphenylsiloxane, polyalkylsiloxane, organo-modified silicones such as, for example, polyetherpolysiloxane copolymers, fluorosililicones or hydrosilicones, more preferably polydimethylsiloxane.
  • the active substance depots are spherical and have a diameter of from 10 to 2,000, preferably from 100 to 1,000 and particularly preferably from 300 to 850 ⁇ m. The adjustment of the diameter can be done by screening. Such drug depots allow a particularly uniform release of the active ingredient contained over a period of 3 to 7 days.
  • the content of the active ingredient in the active substance depots can be in particular 2 to 60, preferably 2 to 50, more preferably 5 to 40 and particularly preferably 5 to 30% by weight.
  • This active substance content represents an optimum from manufacturability of the particles, reservoir effect and release kinetics. It is furthermore advantageous if the substrate contains 0.1 to 20, preferably 0.5 to 15, more preferably 1 to 10 and particularly preferably 1 to 5% by weight.
  • the drug depots, based on the total weight of the wound dressing contains.
  • such wound dressings show comparable mechanical and haptic properties as corresponding active substance depot-free wound dressings, and the outer appearance of the wound dressing is not appreciably changed by the inked silicone particles.
  • Another object of the invention is a wound dressing according to the invention for use as a wound treatment agent.
  • a wound dressing according to the invention for the production of an agent for the treatment of wounds.
  • the solids contents were determined according to DIN-EN ISO 3251.
  • NCO contents were determined volumetrically in accordance with DIN-EN ISO 11909, unless expressly stated otherwise.
  • the determination of the mean particle sizes (indicated by the number average) of the polyurethane dispersion 1 was carried out by means of laser correlation spectroscopy (apparatus: Malvern Zetasizer 1000, Malver Inst. Limited).
  • the indicated viscosities were determined by means of rotational viscometry according to DIN 53019 at 23 ° C. with a rotational viscometer from Anton Paar Germany GmbH, Ostfildern, DE.
  • Diaminosulphonate NH 2 -CH 2 CH 2 -NH-CH 2 CH 2 -SO 3 Na (45% in water)
  • Desmophen ® C2200 polycarbonate polyol, OH number 56 mg KOH / g, number average molecular weight 2000 g / mol (Bayer Materials cience AG, Leverkusen, DE)
  • PolyTHF 2000 polytetramethylene glycol polyol, OH number 56 mg KOH / g, number average molecular weight 2000 g / mol (BASF AG, Ludwigshafen, DE)
  • PolyTHF 1000 polytetramethylene glycol polyol, OH number 1 12 mg KOH / g, number-average number average molecular weight 1000 g / mol (BASF AG, Ludwigshafen, DE)
  • Polyether LB 25 mono-functional polyether based on ethylene oxide / propylene oxide, number-average molecular weight 2250 g / mol, OH number 25 mg KOH / g (Bayer Materials Science AG, Leverkusen, DE)
  • Arg-HCl L-arginine hydrochloride (Sigma, Steinheim, DE) Sylgard ® 184; Comp. A: dimethylvinyl-terminated dimethylsiloxane (Dow Corning SA, Seneffe, BE)
  • Syl-Off ® 4000 platinum Organic Catalyst (Dow Corning SA, Seneffe, BE)
  • Pluronic ® F127 EO / PO block copolymer (BASF, Ludwigshafen, DE)
  • Pluronic ® PE6800 EO / PO block copolymer (BASF, Ludwigshafen, DE)
  • Desmodur ® N 3400 Aliphatic polyisocyanate (HDI uretdione), NCO content 21.8%
  • DBU 1, 8-diazabicyclo (5.4.0) undec-7-ene
  • the resulting polyurethane dispersion had the following properties:
  • silicone particles of the cooled suspension were separated with the aid of metal sieves into three fractions (0 ⁇ 300 ⁇ m, 300 ⁇ m ⁇ 0 ⁇ 850 ⁇ m, 0> 850 ⁇ m) and washed with water and methanol. The particles were annealed overnight at 50 ° C under vacuum.
  • FIG. 1 shows the concentrations of the released arginine which are not cumulated: Within a few hours, the therapeutically necessary Arg concentration of 100 ⁇ mol / L is reached and maintained for about 3 days, which corresponds to the usual residence time of a wound dressing on a corresponding wound. The drug reservoir is not exhausted even after 5-7 days.
  • polyurethane dispersion 1 100 g of polyurethane dispersion 1, prepared according to Example 1 were mixed with 9.9 g of a 30% solution of Pluronic ® PE 6800 in water and opened using a commercially available hand stirrer (stirrer made of bent wire) to 400 mL of foam volume. Thereafter, the foam was applied by means of film applicator (squeegee) with gap height 2 mm on non-stick paper, while still wet with 6.37 g of silicone particles 1, prepared according to Example 2, sprinkled. Now, a further foam layer was applied by means of a film-drawing device to the first still moist foam layer such that the silicone particles were enclosed on both sides by polyurethane foam. The composite material was dried at 120 ° C for 20 minutes in a convection oven. There were pure white foam silicone particle composite materials with good mechanical
  • peel strength> 0.8 N / mm in the peel test 0.8 N / mm in the peel test
  • the peel strength also called peel strength, was determined on a Zwick universal testing machine. For this purpose, the two foam layers were subtracted from each other at an angle of 180 ° at a crosshead speed of 100 mm / min.
  • the silicone particles 1 prepared according to Example 2 were then sprinkled like an island on this dried foam, covered with a further foam layer and the two foam layers at 160 ° C for 60 s to a thickness of 1 mm, ie 25% of the original thickness, pressed together, that the silicone particles in the resulting foam bag were enclosed on all sides in the foam.
  • Example 7 Preparation of a Silicone Particle-Containing Polyurethane Reactive Foam

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Materials Engineering (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Polyurethanes Or Polyureas (AREA)

Abstract

L'invention concerne un pansement comprenant un substrat absorbant les liquides contenant un dépôt de principe actif, le dépôt de principe actif comprenant des particules d'au moins un principe actif, qui sont encapsulées dans une enveloppe de silicone. L'invention concerne en outre un pansement selon l'invention destiné à être utilisé en tant que moyen destiné au traitement de blessures, ainsi que l'utilisation d'un pansement selon l'invention pour la production d'un moyen destiné au traitement de blessures.
EP11702068A 2010-02-11 2011-02-08 Pansement à libération de principe actif Withdrawn EP2534187A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11702068A EP2534187A1 (fr) 2010-02-11 2011-02-08 Pansement à libération de principe actif

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10001400 2010-02-11
PCT/EP2011/051804 WO2011098444A1 (fr) 2010-02-11 2011-02-08 Pansement à libération de principe actif
EP11702068A EP2534187A1 (fr) 2010-02-11 2011-02-08 Pansement à libération de principe actif

Publications (1)

Publication Number Publication Date
EP2534187A1 true EP2534187A1 (fr) 2012-12-19

Family

ID=42543018

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11702068A Withdrawn EP2534187A1 (fr) 2010-02-11 2011-02-08 Pansement à libération de principe actif

Country Status (3)

Country Link
US (1) US20130136785A1 (fr)
EP (1) EP2534187A1 (fr)
WO (1) WO2011098444A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2868679B1 (fr) * 2012-06-29 2019-01-09 Tosoh Corporation Composition catalytique, destinée à la préparation d'une résine de polyuréthane et procédé de préparation d'une résine de polyuréthane à l'aide de ladite composition catalytique
KR20200108279A (ko) * 2018-01-12 2020-09-17 코베스트로 인텔렉쳐 프로퍼티 게엠베하 운트 콤파니 카게 탄성 및 인열-내성 폴리우레탄 발포체의 제조 방법 및 그의 용도
WO2019137879A1 (fr) * 2018-01-12 2019-07-18 Covestro Deutschland Ag Procédé de fabrication de mousses de polyuréthane à faible gonflement et leurs applications

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789739A (fr) 1971-10-05 1973-04-05 Lock Peter M Pansement chirurgical
US3978266A (en) 1972-10-05 1976-08-31 Ionics Lyo Products Company Surgical dressings
DE2446440C3 (de) 1974-09-28 1981-04-30 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von wäßrigen Dispersionen von Sulfonatgruppen aufweisenden Polyurethanen
NZ199684A (en) * 1981-02-13 1985-03-20 Smith & Nephew Ass Wound dressing;wound facing layer a conformable elastomeric integral net
US4597960A (en) * 1983-04-19 1986-07-01 Cohen Edgar C Microencapsulated astringent hemostatic agents and methods of use
US5232769A (en) 1989-08-01 1993-08-03 Kanebo, Ltd. Microcapsule, treating liquids containing the same, and textile structure having microcapsules adhering thereto
DE19750186A1 (de) 1997-11-13 1999-05-20 Bayer Ag Hydrophilierungsmittel, ein Verfahren zu dessen Herstellung sowie dessen Verwendung als Dispergator für wäßrige Polyurethan-Dispersionen
DE10024624A1 (de) 2000-05-18 2001-11-22 Bayer Ag Modifizierte Polyisocyanate
DE102005060461A1 (de) 2005-12-17 2007-07-12 Paul Hartmann Ag Medizinische Zusammensetzung
US20070161936A1 (en) * 2006-01-06 2007-07-12 Svetlik Harvey E Wound treatment-dressing and method of manufacture
DE102007048079A1 (de) * 2007-10-05 2009-04-09 Bayer Materialscience Ag Verfahren zur Herstellung von Polyurethan-Schäumen
DE102007048078A1 (de) * 2007-10-05 2009-04-09 Bayer Materialscience Ag Polyurethan-Schäume für die Wundbehandlung
EP2143744A1 (fr) * 2008-07-09 2010-01-13 Bayer MaterialScience AG Mousses de polyuréthane hydrophile et aliphatique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011098444A1 *

Also Published As

Publication number Publication date
US20130136785A1 (en) 2013-05-30
WO2011098444A1 (fr) 2011-08-18

Similar Documents

Publication Publication Date Title
EP2015786B1 (fr) Articles moussants biomédicaux
EP2010235B1 (fr) Procede de fabrication de mousses de polyurethanne
EP2704754B1 (fr) Mousse de polyuréthane hydrophile au gonflement volumique minime
EP2197930B1 (fr) Procédé de fabrication de mousses de polyuréthane
EP2389400B1 (fr) Utilisation de mousses de dispersions polyuréthane à deux composants comme pansement pour plaie
EP2389402B1 (fr) Mousses de polyuréthanes stabilisées par tensioactif à base de polyuréthane
EP2470580B1 (fr) Mousses de polyuréthane aliphatiques hydrophiles
EP2632501B1 (fr) Mousses polyuréthanne aliphatiques hydrophiles
DE102007048080A1 (de) Biomedizinische Schaumartikel
EP2045279A1 (fr) Mousses de polyuréthane pour le traitement de plaies
EP2183309A1 (fr) Copolymères séquencés eo/po utilisés comme agents stabilisants pour des mousses polyuréthane
DE102007048078A1 (de) Polyurethan-Schäume für die Wundbehandlung
DE102007048079A1 (de) Verfahren zur Herstellung von Polyurethan-Schäumen
EP2523988A1 (fr) Mousses de polyuréthane aliphatique hydrophile
EP2760488B1 (fr) Mousse à pulvériser alkoxysilane à durcissage rapide
EP3737429B1 (fr) Procédé de production de mousses de polyuréthane élastiques et résistantes à la déchirure ainsi que leurs applications
WO2011069972A2 (fr) Mousses de polyuréthane aliphatique hydrophiles
WO2013000910A1 (fr) Mousse de liaison pour des pansements
WO2011098444A1 (fr) Pansement à libération de principe actif
EP2760903B1 (fr) Mousses d'alkoxysilane à atomiser durcissant rapidement

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120911

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MAGER, MICHAEL

Inventor name: KLEE, DORIS

Inventor name: HECKROTH, HEIKE

Inventor name: WAMBACH, MONA

Inventor name: SUSCHEK, CHRISTOPH

Inventor name: SCHOENBERGER, JAN

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140902